Answers are grounded in this paper and cite their sources.
Crohn’s disease (CD) is associated with gut microbial dysbiosis, but the functional contributions of individual bacterial species remain incompletely understood. Here, we analyzed fecal samples from CD patients and assessed the effects of Bacteroides acidifaciens (B. acidifaciens) in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis and interleukin-10 (IL-10) knockout mouse models of colitis, as well as in antibiotic-treated mice. Fecal B. acidifaciens abundance was increased in CD patients compared with controls and in these murine models, and its abundance correlated with disease activity and inflammatory markers in patients. Functionally, administration of B. acidifaciens exacerbated colitis in experimental models and increased intestinal permeability in antibiotic-treated mice. In vitro, both live B. acidifaciens and its culture supernatant impaired epithelial barrier function and reduced tight-junction protein levels. The serine protease inhibitor 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) attenuated these barrier-disrupting effects, suggesting that secreted serine proteases contribute to barrier injury. Although the specific proteases require further validation, these findings indicate that B. acidifaciens acts as a disease-relevant effector via secreted serine proteases, highlighting bacterial proteases as potential targets for restoring mucosal barrier integrity in CD.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: